این سایت در حال حاضر پشتیبانی نمی شود و امکان دارد داده های نشریات بروز نباشند
Basic and Clinical Cancer Research، جلد ۱۲، شماره ۱، صفحات ۱۸-۲۵
عنوان فارسی
چکیده فارسی مقاله
کلیدواژه‌های فارسی مقاله
عنوان انگلیسی Inutility of IMP3 Marker in Differentiating Hodgkin Lymphoma from Large Cell Lymphoma
چکیده انگلیسی مقاله Background: Hodgkin’s lymphoma is one of the most commonly diagnosed lymphomas in Western society. Today Reed-Sternberg cells are identified by positive staining of several biomarkers. The IMP3 (insulin-like growth factor II m-RNA-binding protein 3) marker is a member of the insulin-like growth factor II mRNA binding protein family that has been suggested as a diagnostic marker in some epithelial malignancies. In this study, we aimed to evaluate the expression profile of IMP3 in Hodgkin’s lymphoma patients and compare it with those with large cell lymphoma. Methods: In this study, patients diagnosed with Hodgkin’s lymphoma between 2016 and 2018 were recruited. For the control group, patients diagnosed with large cell lymphoma were chosen. Paraffin blocks were collected and cut by a microtome machine. Immunohistochemical staining was performed on the slides for the IMP3 marker, using the Envision method. The color intensity was divided into four groups, and data on age, gender, staining intensity, sampling rate, and staining pattern entered at the end of the checklists. The collected data were analyzed using SPSS 19 software. The paired t-test has was employed, and a significant statistical level of 0.05 was considered in all tests. Results: In this study, 145 patients in a wide range of 5 to 84 years (the mean age = 41 ± 17 years) were studied. Fifty-three patients were diagnosed with diffuse large B-cell lymphoma (36.6%), 4 cases (2.8%) with anaplastic large cell lymphoma and 88 cases with (60.7%) Hodgkin’s lymphoma. Among 145 patients in the current study, 143 patients (98.6%) were positive for IMP3. IMP3 was positive in all patients with Hodgkin’s lymphoma and anaplastic large cell lymphoma, and only 2 cases of diffuse large B-cell lymphoma were negative for this maker, in whom severe necrosis was noted. Consequently, there is not a vivid difference between Hodgkin’s lymphoma and non-Hodgkin’s lymphoma (p-value=0.153) Conclusion: The marker is positive for Hodgkin’s lymphoma with a negative background and may be used as a supplementary marker along with CD15 and CD30 to detect neoplastic cells. However, it cannot help differentiate it from large cell lymphomas because it is also positive for non-Hodgkin lymphomas.
کلیدواژه‌های انگلیسی مقاله
نویسندگان مقاله | Ali Zare Mehrjerdi
Associate Professor of Pathology, Department of Pathology, School Of Medicine, Iran University Of Medical Sciences, Tehran, Iran


| Mahdie Ahmadi
Department Of Pathology, School Of Medicine, Iran University Of Medical Sciences, Tehran, Iran
نشانی اینترنتی https://bccr.tums.ac.ir/index.php/bccrj/article/view/351
فایل مقاله فایلی برای مقاله ذخیره نشده است
کد مقاله (doi)
زبان مقاله منتشر شده
موضوعات مقاله منتشر شده
نوع مقاله منتشر شده
برگشت به: صفحه اول پایگاه   |   نسخه مرتبط   |   نشریه مرتبط   |   فهرست نشریات